Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference
February 14 2018 - 4:00PM
Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I.
Blum, President and Chief Executive Officer, is scheduled to
present a corporate update at the RBC Capital Markets Global
Healthcare Conference on Thursday, February 22, 2018 at 10:00 AM ET
at the Lotte New York Palace Hotel in New York.
Interested parties may access the live webcast
of this presentation by visiting the Investors & Media section
of the Cytokinetics website at www.cytokinetics.com. The webcast
replay of the presentation will be archived on the Presentations
page within the Investors & Media section of Cytokinetics'
website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a late-stage
biopharmaceutical company focused on discovering, developing and
commercializing first-in-class muscle activators as potential
treatments for debilitating diseases in which muscle performance is
compromised and/or declining. As a leader in muscle biology and the
mechanics of muscle performance, the company is developing small
molecule drug candidates specifically engineered to increase muscle
function and contractility. Cytokinetics is collaborating
with Amgen Inc. (“Amgen”) to develop omecamtiv
mecarbil, a novel cardiac muscle activator. Omecamtiv
mecarbil is the subject of GALACTIC-HF, an international Phase
3 clinical trial in patients with heart
failure. Amgen holds an exclusive worldwide license to
develop and commercialize omecamtiv mecarbil with a
sublicense held by Servier for commercialization
in Europe and certain other
countries. Cytokinetics is collaborating
with Astellas Pharma Inc. (“Astellas”) to develop
CK-2127107, a next-generation FSTA. CK-2127107 has been granted
orphan drug designation by the FDA for the potential
treatment of spinal muscular atrophy (SMA.) CK-2127107 is the
subject of three ongoing Phase 2 clinical trials enrolling patients
with SMA, COPD and ALS. Astellas is also conducting a Phase 1b
clinical trial of CK-2127107 in elderly adults with limited
mobility. Astellas holds an exclusive worldwide license to develop
and commercialize CK-2127107. Licenses held by Amgen and
Astellas are subject to Cytokinetics' specified
co-development and co-commercialization
rights. Cytokinetics continues its 20-year history of
innovation with three new muscle biology directed compounds
advancing from research to development in 2018. For
information about Cytokinetics, please
visit www.cytokinetics.com.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Act's Safe Harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating
to Cytokinetics' and its partners' research and
development activities of Cytokinetics’ product candidates. Such
statements are based on management's current expectations, but
actual results may differ materially due to various risks and
uncertainties, including, but not limited to the risks related
to Cytokinetics' business outlined
in Cytokinetics' filings with the Securities and
Exchange Commission. Forward-looking statements are not guarantees
of future performance, and Cytokinetics' actual results
of operations, financial condition and liquidity, and the
development of the industry in which it operates, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements
that Cytokinetics makes in this press release speak only
as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:
CytokineticsDiane WeiserVice President, Corporate
Communications, Investor Relations(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024